Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | exodeoxyribonuclease III family protein | 0.0019 | 0.4151 | 0.3482 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0027 | 1 | 1 |
Echinococcus granulosus | NADP dependent isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.1996 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0019 | 0.4151 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0019 | 0.4151 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.4151 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0019 | 0.4151 | 0.2693 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.1996 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.9646 | 0.9646 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.1996 |
Echinococcus granulosus | intermediate filament protein | 0.0027 | 1 | 1 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0019 | 0.4151 | 0.5 |
Echinococcus multilocularis | musashi | 0.0027 | 1 | 1 |
Echinococcus multilocularis | isocitrate dehydrogenase 2 (NADP+) | 0.0016 | 0.1996 | 0.1996 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 1 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0019 | 0.4151 | 0.2693 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0019 | 0.4151 | 0.4151 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.4151 | 1 |
Schistosoma mansoni | intermediate filament proteins | 0.0027 | 1 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0.4151 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0019 | 0.4151 | 0.5 |
Onchocerca volvulus | 0.0027 | 1 | 0.5 | |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0019 | 0.4151 | 1 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0019 | 0.4151 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0027 | 1 | 1 |
Echinococcus granulosus | lamin dm0 | 0.0027 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament protein | 0.0027 | 1 | 1 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0019 | 0.4151 | 0.4151 |
Echinococcus granulosus | lamin | 0.0027 | 1 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0019 | 0.4151 | 0.5 |
Schistosoma mansoni | lamin | 0.0027 | 1 | 1 |
Toxoplasma gondii | exonuclease III APE | 0.0019 | 0.4151 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0019 | 0.4151 | 0.5 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0014 | 0.1026 | 0.1026 |
Brugia malayi | isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.108 |
Echinococcus multilocularis | lamin | 0.0027 | 1 | 1 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.1996 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0019 | 0.4151 | 0.4151 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0.4151 | 1 |
Onchocerca volvulus | 0.0027 | 1 | 0.5 | |
Schistosoma mansoni | lamin | 0.0027 | 1 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0019 | 0.4151 | 0.5 |
Loa Loa (eye worm) | isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.1996 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0019 | 0.4151 | 0.5 |
Brugia malayi | Isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.108 |
Echinococcus multilocularis | isocitrate dehydrogenase | 0.0016 | 0.1996 | 0.1996 |
Echinococcus multilocularis | lamin dm0 | 0.0027 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.